Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
visceral fat
Advertisement
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
Eos SENOLYTIX Highlights PTC-2105 Preclinical Data at Obesity Forum
HOUSTON, Texas, June 5, 2026 Eos SENOLYTIX, Inc. presented new preclinical findings for its lead MitoXcel™ geropeptide candidate PTC-2105...
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Advertisement
